DrugPatentWatch Database Preview➤ Subscribe for complete access
« Back to Dashboard
Bimatoprostis the generic ingredient in four branded drugs marketed by Allergan Inc, Akorn, Alembic Pharms Ltd, Apotex Inc, Gland Pharma Ltd, Lupin Ltd, Micro Labs, Sandoz Inc, Somerset Theraps Llc, and Allergan, and is included in sixteen NDAs. There are thirty-two patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.
Bimatoprost has two hundred and thirty-six patent family members in thirty-three countries.
There are twelve drug master file entries for bimatoprost. Nine suppliers are listed for this compound. There are five tentative approvals for this compound.
Summary for BIMATOPROST
|Drug Master File Entries:||12|
|Finished Product Suppliers / Packagers:||9|
|Raw Ingredient (Bulk) Api Vendors:||63|
|Drug Prices:||Drug price trends for BIMATOPROST|
|Drug Sales Revenues:||Drug sales revenues for BIMATOPROST|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for BIMATOPROST|
|What excipients (inactive ingredients) are in BIMATOPROST?||BIMATOPROST excipients list|
|DailyMed Link:||BIMATOPROST at DailyMed|
Recent Clinical Trials for BIMATOPROST
Identify potential brand extensions & 505(b)(2) entrants
|Medical University of South Carolina||Early Phase 1|
|CBCC Global Research||Phase 3|
|Mankind Pharma Limited||Phase 3|
Generic filers with tentative approvals for BIMATOPROST
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for BIMATOPROST
|Drug Class||Prostaglandin Analog |
Medical Subject Heading (MeSH) Categories for BIMATOPROST
|Country||Patent Number||Estimated Expiration|
|Australia||2010227111||⤷ Free Forever Trial|
|Japan||2014058585||⤷ Free Forever Trial|
|Brazil||PI0708622||⤷ Free Forever Trial|
|New Zealand||549516||⤷ Free Forever Trial|
|Poland||1753434||⤷ Free Forever Trial|
|Japan||5826872||⤷ Free Forever Trial|
|Canada||2643903||⤷ Free Forever Trial|
|>Country||>Patent Number||>Estimated Expiration|
|Patent Number||Supplementary Protection Certificate||SPC Country||SPC Expiration||SPC Description|
|0660716||02C0033||France||⤷ Free Forever Trial||PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:|
|0660716||C300099||Netherlands||⤷ Free Forever Trial||PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308|
|0660716||SPC/GB02/035||United Kingdom||⤷ Free Forever Trial||PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308|
|>Patent Number||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration||>SPC Description|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.